JP2003527117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003527117A5 JP2003527117A5 JP2001567795A JP2001567795A JP2003527117A5 JP 2003527117 A5 JP2003527117 A5 JP 2003527117A5 JP 2001567795 A JP2001567795 A JP 2001567795A JP 2001567795 A JP2001567795 A JP 2001567795A JP 2003527117 A5 JP2003527117 A5 JP 2003527117A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- receptor
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 130
- 229920001184 polypeptide Polymers 0.000 description 127
- 102000004196 processed proteins & peptides Human genes 0.000 description 127
- 125000003275 alpha amino acid group Chemical group 0.000 description 59
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 53
- 102000013691 Interleukin-17 Human genes 0.000 description 52
- 108050003558 Interleukin-17 Proteins 0.000 description 52
- 150000007523 nucleic acids Chemical class 0.000 description 40
- 108020004707 nucleic acids Proteins 0.000 description 38
- 102000039446 nucleic acids Human genes 0.000 description 38
- 239000002773 nucleotide Substances 0.000 description 38
- 125000003729 nucleotide group Chemical group 0.000 description 38
- 230000000694 effects Effects 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 26
- 239000012634 fragment Substances 0.000 description 24
- 239000011230 binding agent Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- 239000008194 pharmaceutical composition Substances 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 10
- 239000003446 ligand Substances 0.000 description 9
- 230000001575 pathological effect Effects 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- -1 SEQ ID NO: 5 Chemical group 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OWSRLHPWDZOHCR-UHFFFAOYSA-N 4,4-diaminobutanoic acid Chemical compound NC(N)CCC(O)=O OWSRLHPWDZOHCR-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004554 Interleukin-17 Receptors Human genes 0.000 description 1
- 108010017525 Interleukin-17 Receptors Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18992300P | 2000-03-16 | 2000-03-16 | |
| US60/189,923 | 2000-03-16 | ||
| US20420800P | 2000-05-12 | 2000-05-12 | |
| US60/204,208 | 2000-05-12 | ||
| US72323200A | 2000-11-27 | 2000-11-27 | |
| US09/723,232 | 2000-11-27 | ||
| US26615901P | 2001-02-02 | 2001-02-02 | |
| US60/266,159 | 2001-02-02 | ||
| PCT/US2001/008688 WO2001068705A2 (en) | 2000-03-16 | 2001-03-16 | Il-17 receptor like molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003527117A JP2003527117A (ja) | 2003-09-16 |
| JP2003527117A5 true JP2003527117A5 (enExample) | 2008-04-24 |
Family
ID=27497823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001567795A Pending JP2003527117A (ja) | 2000-03-16 | 2001-03-16 | Ｉｌ−１７レセプター様分子およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1265924A2 (enExample) |
| JP (1) | JP2003527117A (enExample) |
| AR (1) | AR030554A1 (enExample) |
| AU (2) | AU5902901A (enExample) |
| CA (1) | CA2401273A1 (enExample) |
| MX (1) | MXPA02009024A (enExample) |
| TW (1) | TWI322154B (enExample) |
| WO (1) | WO2001068705A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ508878A (en) | 1998-05-15 | 2003-08-29 | Genentech Inc | IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells |
| US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| EP1897945B1 (en) * | 1999-12-23 | 2012-01-18 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
| US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU2007202616B2 (en) * | 2000-06-22 | 2011-08-18 | Amgen Inc. | IL-17 Like Molecules and Uses Thereof |
| MXPA03003407A (es) * | 2000-10-18 | 2004-05-04 | Immunex Corp | Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. |
| WO2004013281A2 (en) * | 2002-08-05 | 2004-02-12 | Eli Lilly And Company | Novel proteins and their uses |
| AU2003267096B9 (en) * | 2002-09-11 | 2010-11-11 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
| JP2009525765A (ja) * | 2006-02-10 | 2009-07-16 | ザイモジェネティクス， インコーポレイテッド | 切断型のｉｌ−１７ｒａ可溶性受容体および炎症において使用する方法 |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP2081585A2 (en) * | 2006-10-13 | 2009-07-29 | The Regents of the University of California | Cancer treatment |
| JP5561689B2 (ja) * | 2007-11-28 | 2014-07-30 | 独立行政法人理化学研究所 | Ｉｌ−１７ｒｂ陽性ｎｋｔ細胞を用いたアレルギー性気道炎症及び／又は気道過敏症の治療薬のスクリーニング方法 |
| KR20170023209A (ko) | 2008-05-05 | 2017-03-02 | 노비뮨 에스 에이 | 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법 |
| GB0905972D0 (en) | 2009-04-06 | 2009-05-20 | Medical Res Council | Antibodies against IL-17BR |
| PE20120815A1 (es) | 2009-05-05 | 2012-07-08 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos |
| IN2012DN06720A (enExample) | 2010-01-15 | 2015-10-23 | Kirin Amgen Inc | |
| SG184195A1 (en) * | 2010-03-30 | 2012-11-29 | Janssen Biotech Inc | Humanized il-25 antibodies |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83878A (en) | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5319071A (en) | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| DE69233441T2 (de) | 1991-04-26 | 2005-10-13 | Osaka Bioscience Institute, Suita | Menschliches Zelloberflächen-Antigen codierende DNA |
| US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
| CA2161015A1 (en) | 1993-05-26 | 1994-12-08 | Tak Wah Mak | Transgenic mammals lacking expression of particular cd45 isoforms |
| US6664107B1 (en) | 1993-05-26 | 2003-12-16 | Ontario Cancer Institute, University Health Network | CD45 disrupted nucleic acid |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| MX9704780A (es) | 1994-12-23 | 1998-05-31 | Uab Research Foundation | Antigeno de fas humano secretado. |
| CA2219080A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamycin-based regulation of biological events |
| DE69739853D1 (de) | 1996-02-28 | 2010-06-02 | Ariad Pharma Inc | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen |
| AU9482498A (en) * | 1997-09-17 | 1999-04-05 | Human Genome Sciences, Inc. | Interleukin-17 receptor-like protein |
| US6482923B1 (en) * | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
| AU2315099A (en) * | 1998-01-09 | 1999-07-26 | Immunex Corporation | Il-17rh dna and polypeptides |
| AR022237A1 (es) * | 1999-01-11 | 2002-09-04 | Schering Corp | Citoquinas mamiferas purificadas; reactivos y metodos relacionados |
| CA2367378A1 (en) * | 1999-04-05 | 2000-10-12 | Incyte Pharmaceuticals, Inc. | Molecules of the immune system |
| AU2001236638A1 (en) * | 2000-02-04 | 2001-08-14 | The Board Of Trustees Of The University Of Arkansas | Evi27 gene sequences and protein encoded thereby |
| EP1255837A2 (en) * | 2000-02-08 | 2002-11-13 | Amgen Inc. | Il-17 like molecules and uses thereof |
| US9100155B2 (en) | 2010-05-03 | 2015-08-04 | Qualcomm Incorporated | Method and apparatus for control and data multiplexing in wireless communication |
| JP6160461B2 (ja) | 2013-11-29 | 2017-07-12 | 富士通株式会社 | 尤度重み付け回路 |
-
2001
- 2001-03-15 AR ARP010101203A patent/AR030554A1/es unknown
- 2001-03-15 TW TW090106157A patent/TWI322154B/zh not_active IP Right Cessation
- 2001-03-16 AU AU5902901A patent/AU5902901A/xx active Pending
- 2001-03-16 JP JP2001567795A patent/JP2003527117A/ja active Pending
- 2001-03-16 WO PCT/US2001/008688 patent/WO2001068705A2/en not_active Ceased
- 2001-03-16 AU AU2001259029A patent/AU2001259029B2/en not_active Ceased
- 2001-03-16 MX MXPA02009024A patent/MXPA02009024A/es active IP Right Grant
- 2001-03-16 CA CA002401273A patent/CA2401273A1/en not_active Abandoned
- 2001-03-16 EP EP01932510A patent/EP1265924A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003527117A5 (enExample) | ||
| JP2004508043A5 (enExample) | ||
| CA2421588A1 (en) | Tnf receptor-like molecules and uses thereof | |
| US7175995B1 (en) | TCL-1 protein and related methods | |
| CA2464121C (en) | Pregnancy-associated plasma protein-a2 (papp-a2) | |
| FR2772047B1 (fr) | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection | |
| EP1604014A4 (en) | GENE EXPRESSION IN BREAST CANCER | |
| US8426144B2 (en) | Monocyte-derived nucleic acids and related compositions and methods | |
| JP2005518212A5 (enExample) | ||
| EP0514481B1 (en) | Merosin, nucleic acids encoding, fragments and uses thereof | |
| JP2002512005A5 (enExample) | ||
| EP1499725A1 (en) | Psp94 binding protein and psp94 diagnostic assays | |
| WO1995016709A2 (en) | Anti-mullerian hormone receptor polypeptides and antibodies thereto | |
| US8323916B2 (en) | Method of detecting endometrial cancer comprising measuring levels of fibrocystin-L | |
| JP2007054072A5 (enExample) | ||
| JP2004514448A5 (enExample) | ||
| CA2393467A1 (en) | Chordin-like molecules and uses thereof | |
| US20050118575A1 (en) | Dendritic cell-derived nucleic acids and related compositions and methods | |
| JP2002500036A (ja) | ヒトｆｋ５０６結合タンパク質 | |
| WO2001002566A1 (en) | Metabotropic glutamate receptors and methods of use therefor | |
| AU2006204988A1 (en) | Identification of phospholipase A2 as target in cancer treatment, with special emphasis on colorectal cancer and its mechanism of action | |
| HK1100566A (en) | Monocyte-derived nucleic acids and related compositions and methods | |
| WO2001048220A1 (en) | A novel polypeptide- serine protease 15 and the polynucleotide encoding said polypeptide | |
| WO2001040299A1 (fr) | Nouveau polypeptide, prolipoproteine humaine 14 peptide signal, et polynucleotide codant pour ce polypeptide | |
| WO2001055399A1 (fr) | Nouveau polypeptide, dipeptide aminopeptidase humaine 28, et polynucleotide codant pour ce polypeptide |